KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma

OBJECTIVES: There is no molecular biomarker available in the clinical practice to assess the prognosis of advanced pancreatic carcinoma. This multicenter prospective study aimed to investigate the role of KRAS mutation subtypes within the primary tumor to determine the prognosis of advanced pancreat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bournet, Barbara, Muscari, Fabrice, Buscail, Camille, Assenat, Eric, Barthet, Marc, Hammel, Pascal, Selves, Janick, Guimbaud, Rosine, Cordelier, Pierre, Buscail, Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822095/
https://www.ncbi.nlm.nih.gov/pubmed/27010960
http://dx.doi.org/10.1038/ctg.2016.18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822095/
https://www.ncbi.nlm.nih.gov/pubmed/27010960
http://dx.doi.org/10.1038/ctg.2016.18

Ejemplares similares